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Objective: Functional somatic syndromes (FSS), deﬁned as physical syndromeswithout knownunderlying organ-
ic pathology, are sometimes regarded as less serious conditions than well-deﬁned medical diseases (MD). The
aims of this study were to evaluate functional limitations in FSS, and to compare the results to MD patients
with the same core symptoms.
Methods: This study was performed in 89,585 participants (age: 44.4±12.4 years, 58.5% female) of the general-
population cohort LifeLines. Quality of Life (QoL) andwork participationwere examined as indicators of function-
al limitations. QoL was assessed with two summary scales of the RAND-36: the physical component summary
(PCS) and the mental component summary (MCS). Work participation was assessed with a self-reported ques-
tionnaire. QoL andwork participationwere compared between FSS andMD patients, using Chi-squared tests and
ANCOVA-analyses, adjusted for age, sex, educational level, and mental disorders.
Results: Of the participants, 11.0% (n=9861) reported a FSS, and 2.7% (n=2395) reported a MD. Total QoL, PCS
and MCS were signiﬁcantly lower in all separate FSS and MD compared to controls (P≤ .001). Clinically relevant
differences in QoL were found between chronic fatigue syndrome and multiple sclerosis patients, and between
ﬁbromyalgia syndrome and rheumatoid arthritis patients. Compared to controls, FSS and MD patients reported
a comparably reduced working percentage, increased sick absence, early retirement due to health-related
reasons, and disability percentage (P≤ .001).
Conclusion: Functional limitations in FSS patients are common, and as severe as those in patients with MDwhen
looking at QoL and work participation, emphasizing that FSS are serious health conditions.© 2015 Elsevier Inc. All rights reserved.Introduction
The experience of physical symptoms in the general population is
common [1]. When medical evaluation does not reveal sufﬁcient ex-
planatory pathology, these symptoms are referred to as functional so-
matic symptoms. Functional somatic symptoms often occur together
resulting in functional somatic syndromes (FSS). Chronic fatigue syn-
drome (CFS), ﬁbromyalgia syndrome (FMS), and irritable bowel syn-
drome (IBS) are the most well-known FSS. CFS is mainly characterized
by fatigue without sufﬁcient explanatory pathology [2], FMS patients
suffer from musculoskeletal pain with unknown etiology [3], and IBS, ﬁbromyalgia syndrome; FSS,
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ens).patients suffer from bowel complaints with unknown underlying pa-
thology [4]. These core symptoms are typically accompanied by various
additional symptoms. The etiology of all FSS is assumed to be multifac-
torial involving biological, psychological, and social factors [5].
Because physicians cannot ﬁnd a disease-based explanation for
these syndromes nor always offer appropriate treatment, they ﬁnd it
often difﬁcult to deal with FSS. Physicians might also be frustrated as a
result of difﬁculties in controlling the symptoms and the patients’ emo-
tional responses to the syndromes [6]. Furthermore, it is often assumed
that functional limitations in FSS patients are less severe than those in
patients with well-deﬁned medical diseases (MD). To date, relatively
little is known about functional limitations in FSS patients compared
to MD patients. FSS patients have been shown to suffer from productiv-
ity loss in daily activities, and from social isolation [7,8]. Several studies
suggest that Quality of Life (QoL) is impaired in FSS patients [9–11]. For
instance, overall QoL scores in CFS patients were signiﬁcantly lower
than in other chronic illness groups [12]. QoL and functional disabilities
among patients with FMS have been found to be similar to or worse
than QoL in patients with rheumatoid arthritis (RA), Parkinson’s dis-
ease, and other pain conditions [11,13–15]. Signiﬁcantly lower QoL
scoreswere found in IBS patients as compared to the general population
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bowel disease (IBD) [18]. While previous studies only compared one
FSS and MD, we aimed to compare multiple FSS and MD in one cohort,
thereby avoiding differences in selection procedure or measurement.
FSS are associated with relevant indirect costs [8]. A recent study
showed that costs for healthcare services use and work-related costs
in functional somatic symptoms were estimated to be €6815±10,923
per patient per year [19,20]. Work-related costs are predominantly
caused by productivity loss at work (56%), early retirement (29%), and
sickness absence (14%) [21]. Moreover, high levels of somatic symp-
toms are a determinant of long-term sickness absence, health-related
job loss, and work disability [22]. FSS patients often encounter difﬁcul-
ties at work, as a result of the somatic symptoms [8,23]. For instance,
fatigue is signiﬁcantly inﬂuencing work participation in FSS patients
resulting in more productivity loss at work and sickness absence [24,
25]. Because there are no studies that compare work participation
between FSS and MD patients, it is unknown to what extent work par-
ticipation is affected in FSS patients compared to MD patients.
The aim of the current study was to compare functional limitations
in FSS patients, MD patients, and controls (deﬁned by the absence of
self-reported FSS or MD). We hypothesize that FSS and MD are both
associated with functional limitations. This study is based on data of
LifeLines, a large population-based cohort study. To the best of our
knowledge, there are no studies that evaluate functional limitations in
both FSS and MD patients in one cohort. CFS patients were compared
with patients who suffer from multiple sclerosis (MS), because fatigue
is the most common symptom experienced by persons with MS [26].
FMS patients were comparedwith RA patients, because they share sim-
ilar symptoms including pain and sleep disorders [27]. Lastly, IBS pa-
tients were compared with IBD patients, consisting of Crohn’s disease
and ulcerative colitis, because they sharemany of the clinical symptoms
of IBS [28].
Methods
Sampling frame
This study was conducted within the sampling frame of the Life-
Lines cohort study. LifeLines is a multi-disciplinary, prospective
(three-generational) population-based cohort study examining
health and health-related behaviors of 165,000 persons living in
the North East part of The Netherlands. LifeLines employs a broad
range of investigative procedures in assessing biomedical, socio-
demographic, behavioral, physical and psychological factors which
contribute to the health and disease of the general population, with
a special focus on multimorbidity and complex genetics [29].
Recruitment
Participants of LifeLines were recruited in two ways. First, a number
of general practitioners from the three northern provinces of the
Netherlands invited all their listed patients between 25 and 50 years
of age to participate. If they agreed to participate, these participants
were asked to invite their partner(s), parents, parents in law, and
children to participate as well. In this way participants of all ages were
included. Eligibility for participation was evaluated by general practi-
tioners. To ensure the reliability of the study, persons with severe psy-
chiatric or physical illness, and those not being able to visit the general
practitioner, to ﬁll in the questionnaires, and/or to understand the
Dutch languagewere excluded. Parents and childrenwere not excluded
in case of the mentioned criteria when a representative was willing to
assist these participants in the performance of the study. Inclusion of
pregnant women was rescheduled until 6 months after pregnancy or
3 months after breastfeeding. Second, persons who were interested to
participate could register themselves via the LifeLines website.All participants received written information on the purpose and
methods of the study and written informed consent was obtained
after the procedure was fully explained. All data are kept conﬁdential
and are only used for medical research. Approval by the Medical Ethical
Committee of the University Medical Center Groningen was obtained
for the study.Measures
Functional somatic syndromes and well-deﬁned medical diseases
FSS and MD were assessed by questionnaire, including a list of
chronic disorders with three FSS (irritable bowel syndrome, ﬁbromyal-
gia syndrome, chronic fatigue syndrome) and four MD (Crohn’s disease
and ulcerative colitis, multiple sclerosis and rheumatoid arthritis). Par-
ticipants were asked to indicate which of these diseases they have or
have had, with more than one answer allowed. IBD was deﬁned as the
presence of Crohn’s disease or ulcerative colitis. Controls were deﬁned
by the absence of the self-reported FSS or MD on which this study fo-
cused. To deﬁne a more strict diagnosis, FSS patients with a comorbid
MD were excluded, including CFS patients who reported comorbid MS
(N=6), FMS patients who reported comorbid RA (N=196), IBS patients
who reported comorbid IBD (N=103), and other combinations (N=
258). Furthermore, participants who reported more than one FSS (N=
1281) (for more details, see (30)) or MD (N=29) were excluded, so
that the different groups present their own corresponding core
symptom.Functional limitations
The RAND-36 was used to evaluate health-related QoL [31]. The
RAND-36 consists of 36 closed-ended, structured questions that mea-
sure QoL in eight subscales (physical functioning, role limitations due
to physical health, role limitations due to emotional problems, energy/
fatigue, emotional well-being, social functioning, pain, general health).
The subscales were summarized in two components: the physical com-
ponent summary (PCS) and mental component summary (MCS). The
PCS includes physical function, role physical, bodily pain, and general
health, while the MCS includes vitality, social function, role emotional,
and mental health. The PCS, MCS, and total QoL score were calculated
as recommended by the RAND-36 guideline [32], to generate a score
from 0 to 100, with 0 being the lowest score and 100 being the best
score for QoL. The outcome measures were transformed in T-scores
performing a Z-score transformation ([Z∗10]+50). The T-score with
themean of 50 and an SD of 10 is the average for the Dutch population.
Thereafter, summary score coefﬁcients of the RAND-36 were used to
calculate the PCS, MCS and total QoL score [32]. A minimum difference
of three points on any given RAND-36 scale was considered clinically
relevant [31]. The RAND-36 is validated in the general population and
for patients suffering from several medical conditions [31].
Work participation was assessed with a self-reported questionnaire,
including the following questions: “Which situation applies to you?”
(answer categories: working, retired; early retired; unemployed/
looking for work; disabled for work; welfare; homemaker; study), and
“On average how many hours per week do you spend on paid work?”.
Participants who indicated they were early retired, the reason for stop
working was asked (answer categories: retirement; illness/unﬁt for
work; dismissal/unemployment; other). Participants who indicated
that they were disabled for work were asked for what percentage they
were disabled for work (ranging between 0–100%). According to the
deﬁnition of Statistics Netherlands, theworking populationwas deﬁned
working ≥12 h per week [33]. Sick leave was assessed by the following
questions: “In the past 3 months, how many days did you not work
because of an illness or health problems?”, and “In the past year, how
often did you stay home from work because of an illness or health
problems?”. Sick leave frequency was dichotomized (b4 and ≥4 days).
Table 2
General characteristics of the study groups
N (%) Female
%
Age (years)
Mean (SD)
Education %
Low–middle–high
Controls 77,329 (84.8) 55.6 44.2 (12.3) 28.7
39.1
30.0
Chronic fatigue
syndrome
666 (0.8) 60.5a,b 44.8 (11.3) 30.5
40.8
24.8a
Multiple sclerosis 198 (0.2) 76.8c,d 44.9 (9.7) 30.3
42.9
25.3
Fibromyalgia
syndrome
1686 (1.9) 90.4c,e 48.5 (10.5)c,e 44.0
38.3
14.5c,e
Rheumatoid arthritis 1572 (2.0) 60.8c,f 53.2 (13.2)c,f 44.0
31.0
21.8c,f
Irritable bowel
syndrome
7509 (8.6) 79.2c,g 43.2 (12.1)c,g 29.1
40.1
28.4a
Inﬂammatory bowel
disease
625 (0.7) 61.0a,h 45.9 (10.7)c,h 31.4
39.8
27.2
a P≤ .05 versus controls.
b P≤ .001 versus MS patients.
c P≤ .001 versus controls.
d P≤ .001 versus CFS patients.
e P≤ .001 versus RA patients.
f P≤ .001 versus FM patients.
g ≤ .001 versus IBD patients.
h ≤ .001 versus IBS patients.
Table 3
Prevalence rates of mental disorders
Mood disordera Anxiety disorderb Mood and/or anxiety disorder
Controls 4.3 8.4 9.0
CFS 17.0 23.0 26.4
MS 6.6 9.6 11.1
CFS vs MS
(P-value)c
≤ .001 ≤ .001 ≤ .001
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Information on age and sex was obtained by questionnaire. Educa-
tional levelwas assessed using the question: “What is yourhighest com-
pleted education?”, resulting in information about low, middle, and
high educational level. Low educational level was deﬁned as lower sec-
ondary education or less, middle educational level was deﬁned as
higher secondary education, and high educational level was deﬁned as
tertiary education.Mental disorders, including currentmajor depressive
disorder, dysthymia, panic disorder with or without agoraphobia, ago-
raphobia without panic disorder, social phobia, and generalized anxiety
disorder were assessed with a standardized diagnostic interview: the
Mini International Neuropsychiatric Interview (MINI) 5.0.0. The MINI
is a brief structured interview for diagnosing psychiatric disorders as
deﬁned by the DSM-IV and ICD-10. A dichotomous variable for mental
disorders (i.e. mood and/or anxiety disorders present or all absent)
was constructed from the MINI interview.
Statistical analyses
All analyses were performed using SPSS version 20. Analyses of
covariance (ANCOVA) with Bonferroni correction were conducted to
examine whether FSS, MD, and controls differed in age, QoL, working
hours, and days of sick leave. The percentage of participants that report-
ed a frequency of sick leave of ≥4 times in the past year was described.
Chi-squared testswere used to examine signiﬁcant differences between
FSS, MD and controls in sex, educational level, work participation, sick
leave frequency, disability, and retirement due to health-related rea-
sons. Analyses with regard to QoL andwork participationwere adjusted
for age, sex, and educational level. Analyses were repeated after an
additional adjustment for mental disorders. Statistical analyses were
adjusted for age, sex, educational level, and mental disorders, because
these factors are known to be related to FSS [2,3,30,34], MD [35–37],
QoL [38,39], and work participation [25,40]. Findings were considered
statistically signiﬁcant when P≤ .05, and clinically relevant with a mini-
mum difference of three points on any given RAND-36 scale.
Results
Demographic and work sample characteristics
Data were available for 89,585 participants, with a mean age of 44.4±12.4 years, and
58.5% female. Of these participants, 11.0% (n=9861) reported one FSS, 2.7% (n=2395) re-
ported one of the speciﬁed MD, and 86.3% reported neither FSS nor MD (n=77,329). An
overview of prevalence rates ofmajor medical conditions (lifetime) in the control popula-
tion are presented in Table 1. Furthermore, prevalence rates of the separate FSS and MD,
and the general characteristics of the study groups are presented in Table 2. Lastly, preva-
lence rates of mental disorders in FSS and MD patients are presented in Table 3.
Functional limitations
Health-related QoL
Total QoL, PCS and MCS were signiﬁcantly lower in all the separate FSS and MD com-
pared to controls (Fig. 1; P≤ .001). In the comparisons between FSS and MD patients, FMS
patients (42.9±8.7) reported a signiﬁcantly lower total QoL score than RApatients (46.3±
8.5). Without adjusting for mental disorder, the total QoL score differed signiﬁcantly be-
tween CFS (39.0±10.8) and MS patients (40.8±10.5; p=.003), and IBS (47.3±8.0) and
IBD patients (48.3±8.1; P≤ .001). After adjusting for mental disorders, these differences
were not statistically signiﬁcant anymore. Furthermore, the PCS was found to beTable 1
Prevalence rates of major medical conditions in controls (lifetime)
n %
Arteriosclerosis 328 0.4
Cancer 3718 4.1
Diabetes 1621 2.1
Hypertension 15,800 20.4
Stroke 475 0.6
Heart failure 517 0.7
Heart infarction 714 0.9
COPD 3545 4.6
Asthma 6162 8.0statistically different between CFS (40.2±10.8) and MS patients (38.3±10.9), and FMS
(39.8±10.2) and RA patients (42.5±10.7), both with and without adjusting for mental
disorders. Lastly, the scores for theMCSwere found to be statistically lower in FSS patients
compared to MD patients in all three comparisons, both with and without adjustment for
mental disorders.
When considering clinically relevant differences, CFS patients reported a clinically
relevant lower MCS compared to MS patients (39.7±11.3 and 45.5±9.0). FMS patients
reported a clinically relevant lower PCS,MCS, and total QoL score compared to RApatients.
No clinically relevant differences between IBS and IBD patients were observed.
Work participation and sick leave
Analyses regarding work participation and sick leave were limited to the working age
population (18 to 65 years). Of our participants, 84,607 (94.4%)were of working age (age:
42.8±10.8 years, 58.8% female); 56,513 (63.1%) of these participants reported to work
12 h per week or more (age: 42.1±9.8 years, 54.8% female).
As shown in Table 4, controls reported higher employment percentages (working
≥12 h per week) than separate FSS and MD groups (P ranging from .02 to ≤ .001). WhenFMS 11.0 18.0 20.1
RA 6.0 10.3 11.3
FMS vs RA
(P-value)c
≤ .001 ≤ .001 ≤ .001
IBS 9.1 16.9 18.0
IBD 4.5 9.0 9.8
IBS vs IBD
(P-value)c
≤ .001 ≤ .001 ≤ .001
Data are presented as %.
CFS=chronic fatigue syndrome,MS=multiple sclerosis, FM=ﬁbromyalgia, RA=rheumatoid
arthritis, IBS=irritable bowel syndrome, IBD=inﬂammatory bowel disease.
a Major depressive disorder, dysthymia.
b Generalized anxiety disorder, social phobia, panic disorder with agoraphobia, panic
disorder without agoraphobia, agoraphobia without panic disorder.
c Using Chi-squared test.
Fig. 1.Differences between the groups with regard to the Quality of Life. QoL=quality of life, PCS=physical component summary,MCS=mental component summary. P≤ .001 for all anal-
yses that compared FSS or MD patients to controls. *P≤ .001 for functional somatic syndrome patients versus well-deﬁned medical disease patients.
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tients, except for FMS (P=.029), RA (P=.046) and IBD patients (P=.002) who worked
less hours than controls. Working FSS and MD patients reported signiﬁcantly more sick
leave days, except for IBD patients (P=.496), and a higher sick leave frequency than con-
trols. When considering the separate syndrome comparisons, only IBS patients worked
signiﬁcantly fewer hours per week compared to IBD patients, and CFS patients reportedTable 4
Work participation and sick leave among the working population (working ≥12 h/week)
Working (%)a,b Working (hours/week)
All Men Women All Men
Controls 67.8 73.8 63.1 33.6 (12.0) 40.5
CFS 50.3 59.6 44.1 33.5 (15.3) 40.6
MS 46.3 59.1 42.5 30.2 (12.6) 38.6
CFS vs MS
(P-value)
.333e .593f
.578g
FMS 51.9 61.3 50.9 27.2 (10.4) 40.0
RA 54.4 61.4 49.6 32.2 (12.3) 39.2
FMS vs RA
(P-value)
.193e .885f
.706g
IBS 64.0 70.4 62.4 30.1 (10.8) 39.9
IBD 63.4 70.6 58.8 31.2 (11.1) 37.5
IBS vs IBD
(P-value)
.756e .015f
.015g
CFS=chronic fatigue syndrome, MS=multiple sclerosis, FMS=ﬁbromyalgia syndrome, RA=rh
a Percentage of all participants who are working ≥12 h.
b Chi-squared tests.
c Analyses of covariance.
d ≥4 times of sick leave in the past year.
e Uncorrected using Chi-squared tests.
f Adjusted for age, sex, and educational level.
g Adjusted for age, sex, educational level, and mental disorders.signiﬁcantly lower sick leave days than MS patients, only after the adjustment for mental
disorders.
Retirement and work disability
Overall, controls retired less often due to health-related reasons, and reported a lower
disability percentage than FSS and MD patients (Table 5; P≤ .001). When considering themean (SD)c Sick leave (days/3 months)
mean (SD)c
Frequent sick
leave (%)b,d
Women
(10.6) 27.2 (9.5) 0.8 (3.4) 3.6
(16.1) 27.1 (11.1) 1.5 (4.6) 13.7
(14.0) 26.6 (10.0) 3.0 (7.8) 13.6
.059f .983e
.036g
(11.3) 25.6 (9.0) 1.3 (4.5) 7.6
(11.2) 26.2 (9.7) 1.0 (3.1) 6.3
.716f .296e
.715g
(9.7) 27.3 (9.3) 1.1 (5.3) 6.6
(10.4) 26.5 (9.0) 0.8 (2.6) 7.4
.073f .532e
.118g
eumatoid arthritis, IBS=irritable bowel syndrome, IBD=inﬂammatory bowel disease.
Table 5
Early retirement and work disability among the working age population
Early retirement due to
health-related reasons (%)a
Disability
% Mean (SD)b
Controls 2.0 53.5 (41.6)
CFS 15.4 75.8 (31.9)
MS 20.5 80.1 (28.5)
CFS vs MS
(P-value)
.061c .307d
.094e
FMS 10.8 70.7 (34.6)
RA 7.8 69.4 (34.5)
FMS vs RA
(P-value)
.033c .991d
.852e
IBS 3.4 63.0 (38.6)
IBD 4.7 62.2 (35.5)
IBS vs IBD
(P-value)
.184c .806d
.431e
CFS=chronic fatigue syndrome, MS=multiple sclerosis, FMS=ﬁbromyalgia syndrome,
RA=rheumatoid arthritis, IBS=irritable bowel syndrome, IBD=inﬂammatory bowel
disease.
a Among the participant who indicated that they were early retired using Chi-squared
tests.
b Among the participants who indicated that theywere disabled for work using analyses
of covariance.
c Uncorrected using Chi-squared tests.
d Adjusted for age, sex, and educational level.
e Adjusted for age, sex, educational level, and mental disorders.
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early retirement due to health-related reasons and disability percentage between FSS
and MD patients.Discussion
Our study revealed that functional limitations in FSS patients are
comparable to those in patients with a MD. FSS and MD patients had a
reduced QoL compared to controls. FSS patients reported a lower MCS
compared to MD patients, with relevant clinically differences between
CFS and MS patients, and FMS and RA patients. Controls, FSS, and MD
patients reported a comparable working percentage. However, those
FSS and MD patients that were working, worked fewer hours per
week and reported higher sick absence compared to controls. Thus,
functional limitations in FSS patients are common, and as severe when
looking at QoL and work participation, as those in MD.
Themain strength of this study is the large population-based sample.
This study included a sufﬁcient number of participants with the various
disorders, allowing meaningful cross-group statistical comparisons. Ad-
ditionally, information about the three main FSS and related MD was
availablewhich enabled comparing these FSS andMD in one cohort, lim-
iting differences in selection procedures or measurement. Furthermore,
additional data were available for mental disorders. Since FSS have
frequently been linked to psychopathology [30], it is a major strength
that we were able to adjust our analyses for mental disorders. Especially
because the diagnoses of mental disorders were based on psychiatric
interviews instead of self-reports, that in general give better estimates
of mental disorders. To the best of our knowledge, this is the ﬁrst study
that evaluates functional limitations in FSS and MD patients in one
large population cohort.
There are also several limitations to our study. As a self-reported
questionnaire was used for the diagnosis of FSS and MD as well as for
the assessment of QoL and work participation common method vari-
ance cannot be excluded. Although self-reports may underestimate
the amount of persons with FSS [41], this underestimation seems un-
likely in our study because the prevalence rates for CFS, FMS and IBS
were comparable to those reported in previous studies [2,3,42]. Another
limitation is that lifetime diagnoses of FSS were available instead of cur-
rent diagnoses. A previous study in a general population cohort from the
same geographical area suggests that a vastmajority (i.e. 75%–100%, de-
pending on the syndrome) of the participants that reported a history ofCFS, FMS or IBS, still had this syndrome at the time of reporting [43].
Moreover, the majority of the patients with CFS (N95%) and FMS
(N93%) in the current study recently experienced fatigue and musculo-
skeletal pain in the past week(s). Unfortunately, no information about
recent bowel complaints was available. To overcome the methodologi-
cal weakness of self-reported questionnaires for the diagnosis of FSS
andMD in the future, it is recommended to use patients’ clinical records
when possible. Because LifeLines is a large population cohort study that
aims to study a wide spectrum of mental and somatic disorders, it was
not feasible to more extensively assess the prevalence of the three FSS
during the baseline assessment through practical limitations. We aim
to assess FSS more extensively in future assessment waves, preferably
by the use of clinical records. Furthermore, because of the cross-
sectional design, cause–effect relationships cannot be examined. Lastly,
individuals who fulﬁll criteria for FSS and MD, but did not seek treat-
ment and thus never received a diagnosis might differ from those who
soughtmedical care and received a diagnosis. Our study designmay pri-
marily have sampled FSS andMD patientswho received a diagnosis and
sought medical care, and thus have more limitations than patients who
did not seekmedical care, thereby overestimating functional limitations
in FSS.
Our study supports previous ﬁndings that FSS are associated with
impaired QoL [9,10]. Also in line with earlier studies, MCS were signiﬁ-
cantly lower in CFS and IBS patients than inMS and IBD patients [12,18].
Furthermore, overall QoL, the PCS andMCS scores in FMS patients were
signiﬁcantly lower than in RA patients, which is also in accordancewith
previous ﬁndings [11,13–15]. Although several QoL scores differed sta-
tistically between patients with FSS andMD, not all of these differences
were clinically relevant (i.e. differences larger than three points on the
QoL scale). Nevertheless, CFS patients reported a clinically relevant
lower MCS compared to MS patients, and FMS patients reported a clin-
ically relevant lower PCS, MCS, and total QoL, compared to RA patients.
In addition to previous studies, we found that the lower QoL of FSS pa-
tients compared to MD patients is particularly related to mental limita-
tions. The clinically relevant lower scores in the MCS in CFS and FMS
patients might be due to the difﬁculty in dealing with their disease
symptoms. For instance, FSS patients reported that they felt not be
taken seriously, because the absence of detectable pathology is some-
times interpreted as evidence that their problems are mental rather
than physical [44]. Moreover, FSS patients felt stigmatized, since others
tended to doubt the accuracy and truthfulness of patients’ reported
disabling symptoms [45,46].
Our ﬁndings also indicate that working FSS patients worked equal
numbers of hours per week, and reported equal numbers of sick leave
days compared to MD patients [21]. This indicates that both FSS and
MD are associated with relevant indirect costs [8]. Regarding sick
leave, it is likely that both FSS andMD patients often encounter difﬁcul-
ties at work [8,23]. For example, fatigue is a signiﬁcant problem in both
FSS and MD patients, inﬂuencing work participation [24,25]. Thus, this
may suggest that FSS symptoms affect work participation just like MD
symptoms.
In summary, this population-based study revealed that the function-
al limitations in FSS patients are common and as severe as those in pa-
tients with MD, despite the absence of underlying organic pathology.
It shows that FSS do not only have individual, but also societal conse-
quences. Therefore, health care professionals in public and occupational
health, researchers, and society should pay more attention to these dis-
orders and their consequences in terms of QoL and work participation.
Increased knowledge and understanding of the etiology and impact of
FSS may eventually improve the treatment of a signiﬁcant proportion
of the population (in our cohort 11.0%) who is suffering from FSS. The
study urges the need formore research on FSS, a relatively neglected re-
search area. Especially studies on a better understanding of the etiology
and treatment of these disorders are needed. Speciﬁc suggestions for
studies with regard to QoL and functional limitations are to examine
the cause–effect relationships between FSS and QoL as well as work
99M.L. Joustra et al. / Journal of Psychosomatic Research 79 (2015) 94–99participation, and to gain insight into the working conditions and work
environment of FSS patients.
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